Amadeus Capital Partners and Octopus Ventures co-led the seed round to support product development and team expansion.
"The entire team is very excited about the opportunity that this financing has given us to develop Unlikely AI and its technology, and we are delighted to partner with our new investors."
Octopus Ventures backed the seed round, which will fund product development and team expansion.
"We are incredibly excited to have raised this capital. The seed round will enable us to launch our intelligence layer and gain a unique position within the market to be the first AI-led Customer Success platform. Velaris will serve the entire organisation enabling horizontal growth in other teams and becoming the single source of truth for customer data."
The seed round was led by Faber with participation from international venture funds to support clinical trial operations.
"For hundreds of years, treatments have been developed with the assumption they will work for everyone. However, each person is different, and for many severe diseases such as Alzheimer’s, multiple factors can contribute to the effectiveness of a treatment on a given patient."